NCT01740362

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	CP-690,550	10 mg (2 x 5 mg tablets), single dose
DRUG	CP-690,550	10 mg (2 x 5 mg tablets), single dose
DRUG	CP-690,550	10 mg (2 x 5 mg tablets), single dose
DRUG	CP-690,550	10 mg (2 x 5 mg tablets), single dose

Timeline

• Start date: 2003-10-01
• Primary completion: 2004-03-01
• Completion: 2004-03-01
• First posted: 2012-12-04
• Last updated: 2013-01-07
• Results posted: 2013-01-07

Locations

4 sites across 1 country: United States